Novartis MDx Could See Near-Term Promise in 'Complementary' Diagnostics Over Companion Tests
December 07, 2011
Novartis MDx Could See Near-Term Promise in 'Complementary' Diagnostics Over Companion Tests
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA Approves Pfizer's Chronic Philadelphia Chromosome-Positive CML Drug Bosulif
September 5, 2012 / Pharmacogenomics Reporter - Labceutics, Asuragen Conducting BCR-ABL Quality Assurance Study Among European Labs
March 13, 2013 / Pharmacogenomics Reporter - With Decode Purchase, Amgen Gains Genetics Expertise, Consumers Lose DTC Testing Option
December 12, 2012 / Pharmacogenomics Reporter - Dx Assays Launches Fee-for-Service CDx Development Initiative Giving Pharma More Control
November 2, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: Cepheid Updates BCR-ABL Test; Medicare Covers Transgenomic Plavix Dx; Lungevity Awards
July 25, 2012 / Pharmacogenomics Reporter